Src and focal adhesion kinase as therapeutic targets in cancer

Curr Opin Pharmacol. 2008 Aug;8(4):427-32. doi: 10.1016/j.coph.2008.06.012. Epub 2008 Jul 22.


Over the past few years small molecule inhibitors of both Src family kinases and focal adhesion kinase (FAK) have entered clinical studies for the treatment of solid tumours. These adhesion-linked kinases are involved in a number of pathways that have impact on the behaviour of tumour cells and the challenge is now, how to take these forward in the clinical setting.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Bone Neoplasms / secondary
  • Cell Proliferation / drug effects
  • Focal Adhesion Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Humans
  • Neoplasm Metastasis / drug therapy
  • Neoplasm Metastasis / pathology
  • Neoplasms / drug therapy*
  • Neoplasms / enzymology*
  • Vascular Endothelial Growth Factor A / drug effects
  • Vascular Endothelial Growth Factor A / physiology
  • src-Family Kinases / antagonists & inhibitors*


  • Antineoplastic Agents
  • Vascular Endothelial Growth Factor A
  • Focal Adhesion Protein-Tyrosine Kinases
  • src-Family Kinases